$26.4 M

CATB Mkt cap, 22-Jun-2018
Catabasis Pharmaceuticals Net income (Q1, 2018)-7.7 M
Catabasis Pharmaceuticals EBIT (Q1, 2018)-7.6 M
Catabasis Pharmaceuticals Cash, 31-Mar-201817 M

Catabasis Pharmaceuticals Financials

Catabasis Pharmaceuticals Income Statement

Annual

USDFY, 2015FY, 2016

R&D expense

23 m25.5 m

General and administrative expense

8.6 m10.1 m

Operating expense total

31.7 m35.6 m

EBIT

(31.7 m)(35.6 m)

Interest expense

978 k837 k

Net Income

(32.6 m)(36.1 m)

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

R&D expense

6.4 m6.8 m5.9 m5.4 m4.5 m5.2 m

General and administrative expense

2.8 m2.6 m2.3 m2.4 m2.4 m2.4 m

Operating expense total

9.2 m9.4 m8.3 m7.8 m6.9 m7.6 m

EBIT

(9.2 m)(9.4 m)(8.3 m)(7.8 m)(6.9 m)(7.6 m)

Interest expense

243 k220 k199 k149 k127 k57 k

Net Income

(9.4 m)(9.4 m)(8.4 m)(7.9 m)(7 m)(7.7 m)

Catabasis Pharmaceuticals Balance Sheet

Annual

USDFY, 2015FY, 2016

Cash

62.8 m23.6 m

Inventories

804 k1 m

Current Assets

63.6 m39.5 m

PP&E

504 k568 k

Total Assets

64.2 m40.2 m

Accounts Payable

1.3 m1.4 m

Current Liabilities

7.8 m8.3 m

Total Liabilities

11.1 m

Additional Paid-in Capital

158.5 m173.1 m

Retained Earnings

(108 m)(144.1 m)

Total Equity

50.5 m29.1 m

Financial Leverage

1.3 x1.4 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

23.8 m24.3 m26.5 m31.8 m29.4 m17 m

Current Assets

53.4 m43.7 m48.3 m32.8 m30.3 m17.9 m

PP&E

770 k718 k641 k494 k442 k258 k

Total Assets

54.3 m44.6 m48.9 m33.4 m30.8 m18.3 m

Accounts Payable

1.6 m1.6 m1.7 m942 k2.1 m1.1 m

Current Liabilities

7.4 m7.4 m8.5 m7.5 m8.1 m5.3 m

Total Liabilities

12.5 m11.7 m12.1 m9.5 m9.3 m5.4 m

Additional Paid-in Capital

159.1 m159.7 m172.1 m175.9 m180.4 m192 m

Retained Earnings

(117.4 m)(126.9 m)(135.3 m)(151.9 m)(158.9 m)(179.1 m)

Total Equity

41.7 m32.8 m36.9 m24 m21.6 m12.9 m

Financial Leverage

1.3 x1.4 x1.3 x1.4 x1.4 x1.4 x

Catabasis Pharmaceuticals Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(32.6 m)(36.1 m)

Depreciation and Amortization

202 k395 k

Inventories

(450 k)(229 k)

Accounts Payable

196 k77 k

Cash From Operating Activities

(29.8 m)(32.9 m)

Purchases of PP&E

(421 k)(459 k)

Cash From Investing Activities

(421 k)(15.5 m)

Cash From Financing Activities

78.3 m9.2 m

Interest Paid

684 k582 k

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(9.4 m)(9.4 m)(8.4 m)(7.9 m)(7.7 m)

Depreciation and Amortization

62 k

Accounts Payable

2.5 m1.8 m1.6 m1.6 m1.7 m942 k342 k

Cash From Operating Activities

(6.8 m)

Cash From Financing Activities

7.5 m

Interest Paid

42 k

Catabasis Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.4 x
Report incorrect company information